ESPERION THERAPEUTICS, INC.
ESPR · NASDAQ
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
Market Data
Price
$3.15
+0.00 (+0.00%)
Market Cap$812M
P/E Ratio—
EPS$—
52W High$4.18
52W Low$0.95
Beta1.12
Data from Finnhub · Updated Jun 15, 2026